Interpath Advisory has appointed Jayshree (Jay) Shah as managing director of its value creation team and sector lead for its healthcare and life sciences businesses.

Shah has more than 20 years’ experience of working with corporate and private equity clients covering a range of advisory services, including value creation, commercial and operational pre-deal diligence, business transformation, accelerated operational cost reduction, carve-outs and post-deal integration.

As well as working for PwC and EY in their operational deal advisory teams, Shah is Association of the British Pharmaceutical industry-qualified and has pharmaceutical and healthcare experience having spent half her career working in-house in the industry, including roles at Schering Plough, Datamonitor Pharma and Amdipharm (now Advanz Pharma).

Shah was previously EMEA healthcare and life sciences sector lead in the corporate finance and restructuring practice at FTI. Before that she was European strategy leader at digital interactions company Conduent (formally Xerox).

Shah said: “Joining Interpath provides me with an excellent opportunity to pursue my passion and to make a real difference to organisations in the healthcare and life sciences sector. I’m able to build a team with autonomy that’s not conflicted and draws on specialists from across its multidisciplinary capabilities to deliver meaningful value for clients.

“I’m also focused on further expanding our value creation team itself as part of Interpath’s thriving advisory practice. The pressure has never been greater for investors to create value and have impact which puts at the heart of the M&A market as we support across the deal cycle.”